Abstract

Longnoncoding RNAs (lncRNAs) are significantly correlated with cancer pathogenesis, development, and metastasis. Microarray analysis showed that lncRNA MRPS30-DT is overexpressed in breast carcinoma; however, the function of MRPS30-DT in breast cancer tumorigenesis remains unclear. In situ hybridization and immunohistochemical analysis were used to evaluate the expression levels of MRPS30-DT and Jab1 in clinical samples of breast carcinoma and their relation to survival outcome. qRT-PCR was used to measure MRPS30-DT and Jab1 mRNA expressions. Protein levels were detected using Western blot. Cell proliferation and invasion ability were evaluated via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), colony formation, and transwell assays. MRPS30-DT was knocked down in breast cancer cells to investigate its potential functional roles in cell growth and metastasis in vitro and in vivo. We found that MRPS30-DT was upregulated in breast cancer specimens and was accompanied by high Jab1 expression compared with that of paired para-carcinoma tissues. Knocking down MRPS30-DT significantly inhibited cancer cell proliferation and invasion and induced apoptosis in breast cancer cells. Similarly, knocking down MRPS30-DT in MDA-MB-231 cells significantly suppressed tumor growth. Furthermore, knocking down MRPS30-DT markedly reduced Jab1 expression in breast cancer cells and murine carcinoma. Statistical analyses suggested that high MRPS30-DT or Jab1 levels in breast cancer patients were positively correlated with poor prognoses. These data indicate the possible mechanisms of MRPS30-DT and Jab1 in breast cancer; thus, MRPS30-DT and Jab1 may be novel prognostic biomarkers and potential therapeutic targets for breast cancer treatment.

Highlights

  • Breast cancer is one of the most common malignant tumors in women and is the leading cause of cancer-related death in women [1, 2]

  • We used in situ hybridization and immunohistochemical analysis to evaluate the differential expressions of MRPS30-DT and Jab1 in the breast cancer and matched adjacent tissues

  • Developing secondgeneration sequencing technology has yielded much evidence suggesting that Longnoncoding RNAs (lncRNAs) dysregulation is involved in cancer progression

Read more

Summary

Introduction

Breast cancer is one of the most common malignant tumors in women and is the leading cause of cancer-related death in women [1, 2]. Despite advances in adjuvant therapy in recent years, the 5-year survival rate for patients with advanced breast cancer is only around 22% [5]. Patients who die of metastatic breast cancer account for 90% of these deaths [5]. Precision therapy suggests that different breast cancer subtypes may have different molecular phenotypes and require different treatment strategies [4]. HER2-positive patients have more prolonged survival after targeted anti-HER2 therapy [6]. These features confer different predictive and reactive therapies for breast cancer patients. Novel therapeutic targets for breast carcinoma are urgently needed

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call